Pharmaceutical company Suven Life Sciences said it has been granted product patents for a new compound being developed for the treatment of neurodegenerative diseases in Eurasia, Europe, South Korea and Sri Lanka.
The compounds are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like the Alzheimer’s disease, attention-deficient hyperactivity disorder, Huntington’s disease, Parkinson’s’ and Schizophrenia, the Telangana based pharmaceutical manufacturer said.
A new chemical entity (NCE) is a drug that contains no active molecule that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.
The patents are valid through 2034.
Neurodegeneration is an umbrella term for the progressive loss of structure or function of neurons, including death of neurons.
Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s occur as a result of neurodegenerative processes.
CEO Venkat Jasti said the molecules will address segments with high unmet medical needs with huge, global market potential.
Established in 1989 as a private limited company, Suven went public in 1995. Headquartered in Telangana, Suven designs, manufactures and supplies bulk actives, drug intermediates and fine chemicals to domestic and international players in the bio-pharmaceuticals industry.